{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:40:57Z","timestamp":1792442457778,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Proliferative vitreoretinopathy (PVR) remains the major cause of surgical failure in rhegmatogenous retinal detachment (RRD). This study evaluates the anatomical and functional outcomes, as well as the safety, of a standardized intraoperative intravitreal methotrexate infusion protocol during pars plana vitrectomy (PPV) in eyes with early stage PVR (grade B) or with advanced PVR (grade C).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective case series was conducted on 60 consecutive eyes of 59 patients with RRD and PVR grade B (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200929) or grade C (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200931) undergoing PPV with adjunct intraoperative methotrexate between November 2024 and February 2026 at a German tertiary center. Methotrexate 40\u00a0mg was administered via a 500 mL balanced salt solution infusion. Functional and structural testing included best-corrected visual acuity (BCVA), intraocular pressure, multifocal electroretinogram, perimetry, and spectral-domain optical coherence tomography. The primary outcome measure was single-surgery anatomical success (SSAS) at 12 weeks after primary surgery or after silicone oil removal. Secondary outcomes included BCVA changes and complication rates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SSAS was achieved in 81.7% of all eyes, with a significantly higher success rate in eyes with PVR grade B compared to PVR grade C (93.1% versus 71.0%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.043). At 12 weeks, BCVA improved significantly in macula-off cases (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and remained stable in macula-on cases. In an exploratory subset of 17 patients postoperative multifocal electroretinogram and perimetry demonstrated preserved central retinal function. No ocular or systemic adverse events related to methotrexate occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The standardized intraoperative intravitreal methotrexate infusion protocol was safe, feasible, and associated with high single-surgery reattachment rates, particularly in PVR grade B eyes. Anatomical outcomes in PVR grade C eyes were comparable to other complex PVR cohorts, without any drug-related local or systemic toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Not applicable (retrospective observational study).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-026-05455-8","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:09:32Z","timestamp":1792231772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravitreal methotrexate as a prophylactic strategy for proliferative vitreoretinopathy in high-risk retinal detachment"],"prefix":"10.1186","volume":"26","author":[{"given":"Adrian Konstantin","family":"Luyken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Junge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Armin","family":"Fuchsluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Schaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"issue":"5","key":"5455_CR1","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1097\/IAE.0000000000001302","volume":"37","author":"P Enders","year":"2017","unstructured":"Enders P, Schick T, Schaub F, Kemper C, Fauser S. Risk of multiple, recurring retinal detachment after primary rhegmatogenous retinal detachment repair. Retina Phila Pa. 2017;37(5):930\u20135. https:\/\/doi.org\/10.1097\/IAE.0000000000001302.","journal-title":"Retina Phila Pa"},{"issue":"5","key":"5455_CR2","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/IAE.0000000000004391","volume":"45","author":"D Oncel","year":"2025","unstructured":"Oncel D, Minaker S, Shepherd EA, et al. Risk factors for proliferative vitreoretinopathy in a large clinical database. Retina. 2025;45(5):818\u201326. https:\/\/doi.org\/10.1097\/IAE.0000000000004391.","journal-title":"Retina"},{"issue":"9","key":"5455_CR3","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1136\/bjo.2010.190306","volume":"95","author":"L Wickham","year":"2011","unstructured":"Wickham L, Ho-Yen GO, Bunce C, Wong D, Charteris DG. Surgical failure following primary retinal detachment surgery by vitrectomy: risk factors and functional outcomes. Br J Ophthalmol. 2011;95(9):1234\u20138. https:\/\/doi.org\/10.1136\/bjo.2010.190306.","journal-title":"Br J Ophthalmol"},{"key":"5455_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-025-03846-7","volume":"28","author":"G Hunter","year":"2025","unstructured":"Hunter G, Maclean N, Watson S, et al. Non-surgical interventions for proliferative vitreoretinopathy\u2014a systematic review. Eye Published online May. 2025;28:1\u201319. https:\/\/doi.org\/10.1038\/s41433-025-03846-7.","journal-title":"Eye Published online May"},{"issue":"1","key":"5455_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s10792-026-03963-6","volume":"46","author":"AK Luyken","year":"2026","unstructured":"Luyken AK, Junge V, Schulz A, Fuchsluger TA, Schaub F. Drug strategies for the treatment and prevention of proliferative vitreoretinopathy: an overview of innovative treatment concepts. Int Ophthalmol. 2026;46(1):94. https:\/\/doi.org\/10.1007\/s10792-026-03963-6.","journal-title":"Int Ophthalmol"},{"issue":"1","key":"5455_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00347-020-01173-8","volume":"118","author":"F Schaub","year":"2021","unstructured":"Schaub F, Abdullatif AM, Fauser S, Proliferative Vitreoretinopathieprophylaxe. Ophthalmol. 2021;118(1):3\u20139. https:\/\/doi.org\/10.1007\/s00347-020-01173-8.","journal-title":"Ophthalmol"},{"issue":"6","key":"5455_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00347-026-02427-7","volume":"123","author":"AK Luyken","year":"2026","unstructured":"Luyken AK, Faatz H, Lange C, Boneva SK, Schaub F. [Diseases of the vitreoretinal interface: What role does the vitreous body play?]. Ophthalmol. 2026;123(6):445\u201351. https:\/\/doi.org\/10.1007\/s00347-026-02427-7.","journal-title":"Ophthalmol"},{"key":"5455_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.preteyeres.2013.12.006","volume":"40","author":"S Pennock","year":"2014","unstructured":"Pennock S, Haddock LJ, Eliott D, Mukai S, Kazlauskas A. Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? Prog Retin Eye Res. 2014;40:16\u201334. https:\/\/doi.org\/10.1016\/j.preteyeres.2013.12.006.","journal-title":"Prog Retin Eye Res"},{"key":"5455_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ajo.2017.11.025","volume":"186","author":"CN Roybal","year":"2018","unstructured":"Roybal CN, Velez G, Toral MA, Tsang SH, Bassuk AG, Mahajan VB. Personalized Proteomics in Proliferative Vitreoretinopathy Implicate Hematopoietic Cell Recruitment and mTOR as a Therapeutic Target. Am J Ophthalmol. 2018;186:152\u201363. https:\/\/doi.org\/10.1016\/j.ajo.2017.11.025.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"5455_CR10","doi-asserted-by":"publisher","first-page":"15419","DOI":"10.1038\/s41598-019-51633-8","volume":"9","author":"CW Wong","year":"2019","unstructured":"Wong CW, Cheung N, Ho C, Barathi V, Storm G, Wong TT. Characterisation of the inflammatory cytokine and growth factor profile in a rabbit model of proliferative vitreoretinopathy. Sci Rep. 2019;9(1):15419. https:\/\/doi.org\/10.1038\/s41598-019-51633-8.","journal-title":"Sci Rep"},{"issue":"1","key":"5455_CR11","doi-asserted-by":"publisher","first-page":"936721","DOI":"10.1155\/2012\/936721","volume":"2012","author":"JB Christoforidis","year":"2012","unstructured":"Christoforidis JB, Chang S, Jiang A, Wang J, Cebulla CM. Systemic Treatment of Vitreous Inflammation. Mediators Inflamm. 2012;2012(1):936721. https:\/\/doi.org\/10.1155\/2012\/936721.","journal-title":"Mediators Inflamm"},{"key":"5455_CR12","doi-asserted-by":"publisher","first-page":"1569703","DOI":"10.3389\/fphar.2025.1569703","volume":"16","author":"F Sanie-Jahromi","year":"2025","unstructured":"Sanie-Jahromi F, Ravankhah M, Shafi Khani H, Razavizadegan SA, Nowroozzadeh MH. Effect of methotrexate\/dexamethasone combination on epithelial-mesenchymal transition and inflammation gene expression of human RPE cells in-vitro. Front Pharmacol. 2025;16:1569703. https:\/\/doi.org\/10.3389\/fphar.2025.1569703.","journal-title":"Front Pharmacol"},{"issue":"10","key":"5455_CR13","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1167\/iovs.16-20912","volume":"58","author":"D Amarnani","year":"2017","unstructured":"Amarnani D, Machuca-Parra AI, Wong LL, et al. Effect of Methotrexate on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy. Invest Ophthalmol Vis Sci. 2017;58(10):3940\u20139. https:\/\/doi.org\/10.1167\/iovs.16-20912.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"5455_CR14","doi-asserted-by":"publisher","first-page":"e1070","DOI":"10.1111\/aos.14735","volume":"99","author":"A Schulz","year":"2021","unstructured":"Schulz A, Rickmann A, Julich-Haertel H, et al. Comparative cytotoxic and antiproliferative profile of methotrexate and fluorouracil on different ocular cells. Acta Ophthalmol (Copenh). 2021;99(7):e1070\u20136. https:\/\/doi.org\/10.1111\/aos.14735.","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"2","key":"5455_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.survophthal.2025.09.015","volume":"71","author":"I Kocak","year":"2026","unstructured":"Kocak I, Sayin N, Bayramoglu SE, Thalib L. Effect of methotrexate in preventing retinal detachment after proliferative vitreoretinopathy surgery: A systematic review and meta-analysis. Surv Ophthalmol. 2026;71(2):572\u201381. https:\/\/doi.org\/10.1016\/j.survophthal.2025.09.015.","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"5455_CR16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.oret.2024.10.006","volume":"9","author":"T Liu","year":"2025","unstructured":"Liu T, Runner M, Mahmoud TH, et al. A Modified Intravitreal Methotrexate Protocol for the Prevention of Proliferative Vitreoretinopathy after Silicone Oil Removal. Ophthalmol Retina. 2025;9(4):314\u201321. https:\/\/doi.org\/10.1016\/j.oret.2024.10.006.","journal-title":"Ophthalmol Retina"},{"key":"5455_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-024-03503-5","volume":"14","author":"VTR Toh","year":"2024","unstructured":"Toh VTR, Gerard G, Tay ZQ, Chen J, Chew GWM, Teoh CS. Efficacy and safety of methotrexate in the treatment of proliferative vitreoretinopathy: a systematic review. Eye Published online Dec. 2024;14:1\u20138. https:\/\/doi.org\/10.1038\/s41433-024-03503-5.","journal-title":"Eye Published online Dec"},{"issue":"2","key":"5455_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0002-9394(14)76695-4","volume":"112","author":"R Machemer","year":"1991","unstructured":"Machemer R, Aaberg T, Freeman m, Alexander HM, John RI, Ronald SL. An Updated Classification of Retinal Detachment With Proliferative Vitreoretinopathy. Am J Ophthalmol. 1991;112(2):159\u201365. https:\/\/doi.org\/10.1016\/S0002-9394(14)76695-4.","journal-title":"Am J Ophthalmol"},{"key":"5455_CR19","doi-asserted-by":"publisher","unstructured":"Schwartz SG Jr, Wang HWF, Kuriyan X, Abariga AE, Lee SA. Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy. Cochrane Database Syst Rev. 2020;5. https:\/\/doi.org\/10.1002\/14651858.CD006126.pub4.","DOI":"10.1002\/14651858.CD006126.pub4"},{"issue":"12","key":"5455_CR20","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.oret.2024.06.007","volume":"8","author":"EA Shepherd","year":"2024","unstructured":"Shepherd EA, Minaker SA, Bomdica PR, et al. Risk of Proliferative Vitreoretinopathy in the Second Eye in Adult Patients with Bilateral Retinal Detachment. Ophthalmol Retina. 2024;8(12):1174\u201380. https:\/\/doi.org\/10.1016\/j.oret.2024.06.007.","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"5455_CR21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/IAE.0000000000000307","volume":"35","author":"RR Caiado","year":"2015","unstructured":"Caiado RR, Magalh\u00e3es O, Badar\u00f3 E, et al. Effect of lens status in the surgical success of 23-gauge primary vitrectomy for the management of rhegmatogenous retinal detachment: the Pan American Collaborative Retina Study (PACORES) group results. Retina. 2015;35(2):326\u201333. https:\/\/doi.org\/10.1097\/IAE.0000000000000307.","journal-title":"Retina"},{"key":"5455_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ajo.2024.05.008","volume":"266","author":"RS Huang","year":"2024","unstructured":"Huang RS, Mihalache A, Lau THA, Popovic MM, Kertes PJ, Muni RH. Pars Plana Vitrectomy With Silicone Oil or Gas Tamponade for Uncomplicated Retinal Detachment: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2024;266:144\u201355. https:\/\/doi.org\/10.1016\/j.ajo.2024.05.008.","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"5455_CR23","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/j.ophtha.2006.05.039","volume":"113","author":"PA Quiram","year":"2006","unstructured":"Quiram PA, Gonzales CR, Hu W, et al. Outcomes of vitrectomy with inferior retinectomy in patients with recurrent rhegmatogenous retinal detachments and proliferative vitreoretinopathy. Ophthalmology. 2006;113(11):2041\u20137. https:\/\/doi.org\/10.1016\/j.ophtha.2006.05.039.","journal-title":"Ophthalmology"},{"issue":"2","key":"5455_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00417-020-04923-1","volume":"259","author":"S Dimopoulos","year":"2021","unstructured":"Dimopoulos S, William A, Voykov B, Bartz-Schmidt KU, Ziemssen F, Leitritz MA. Results of different strategies to manage complicated retinal re-detachment. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2021;259(2):335\u201341. https:\/\/doi.org\/10.1007\/s00417-020-04923-1.","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"issue":"4","key":"5455_CR25","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1167\/iovs.15-19030","volume":"57","author":"A Kominami","year":"2016","unstructured":"Kominami A, Ueno S, Kominami T, et al. Restoration of Cone Interdigitation Zone Associated With Improvement of Focal Macular ERG After Fovea-Off Rhegmatogenous Retinal Reattachment. Invest Ophthalmol Vis Sci. 2016;57(4):1604\u201311. https:\/\/doi.org\/10.1167\/iovs.15-19030.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"5455_CR26","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/IAE.0000000000002939","volume":"41","author":"J Kosacki","year":"2021","unstructured":"Kosacki J, Gallice M, Palombi K, et al. Spectral-domain optical, coherence tomography in macula-off rhegmatogenous retinal detachment: a prospective cohort study. Retina. 2021;41(4):744\u201352. https:\/\/doi.org\/10.1097\/IAE.0000000000002939.","journal-title":"Retina"},{"issue":"1","key":"5455_CR27","doi-asserted-by":"publisher","first-page":"28842","DOI":"10.1038\/s41598-024-79708-1","volume":"14","author":"R Nourinia","year":"2024","unstructured":"Nourinia R, Safi S, Mohammadpour M, et al. Effects of repeated intra-silicone oil injections of methotrexate on proliferative vitreoretinopathy grade C: a multicenter randomized controlled trial. Sci Rep. 2024;14(1):28842. https:\/\/doi.org\/10.1038\/s41598-024-79708-1.","journal-title":"Sci Rep"},{"issue":"11","key":"5455_CR28","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1097\/IAE.0000000000004602","volume":"45","author":"JS Yun","year":"2025","unstructured":"Yun JS, Fortes BH, Yamamoto MH, et al. Real-world efficacy of intravitreal methotrexate for managing proliferative vitreoretinopathy in recurrent rhegmatogenous retinal detachment. Retina. 2025;45(11):2086\u201395. https:\/\/doi.org\/10.1097\/IAE.0000000000004602.","journal-title":"Retina"},{"issue":"9","key":"5455_CR29","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/j.ophtha.2014.03.012","volume":"121","author":"RA Adelman","year":"2014","unstructured":"Adelman RA, Parnes AJ, Michalewska Z, Ducournau D, European Vitreo-Retinal Society (EVRS) Retinal Detachment Study Group. Clinical variables associated with failure of retinal detachment repair: the European vitreo-retinal society retinal detachment study report number 4. Ophthalmology. 2014;121(9):1715\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2014.03.012.","journal-title":"Ophthalmology"},{"key":"5455_CR30","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2147\/OPTH.S111893","volume":"10","author":"A Sadaka","year":"2016","unstructured":"Sadaka A, Sisk RA, Osher JM, Toygar O, Duncan MK, Riemann CD. Intravitreal methotrexate infusion for proliferative vitreoretinopathy. Clin Ophthalmol. 2016;10:1811\u20137. https:\/\/doi.org\/10.2147\/OPTH.S111893.","journal-title":"Clin Ophthalmol"},{"key":"5455_CR31","doi-asserted-by":"publisher","first-page":"3648134","DOI":"10.1155\/2021\/3648134","volume":"2021","author":"S El Baha","year":"2021","unstructured":"El Baha S, Leila M, Amr A, Lolah MMA. Anatomical and Functional Outcomes of Vitrectomy with\/without Intravitreal Methotrexate Infusion for Management of Proliferative Vitreoretinopathy Secondary to Rhegmatogenous Retinal Detachment. J Ophthalmol. 2021;2021:3648134. https:\/\/doi.org\/10.1155\/2021\/3648134.","journal-title":"J Ophthalmol"},{"issue":"8","key":"5455_CR32","doi-asserted-by":"publisher","first-page":"e17439","DOI":"10.7759\/cureus.17439","volume":"13","author":"S Jahangir","year":"2021","unstructured":"Jahangir S, Jahangir T, Ali MH, Lateef Q, Hamza U, Tayyab H. Use of Intravitreal Methotrexate Infusion in Complicated Retinal Detachment for Prevention of Proliferative Vitreoretinopathy in a Pilot Study. Cureus. 2021;13(8):e17439. https:\/\/doi.org\/10.7759\/cureus.17439.","journal-title":"Cureus"},{"key":"5455_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2018.03.037","volume":"191","author":"P Foveau","year":"2018","unstructured":"Foveau P, Leroy B, Berrod JP, Conart JB. Internal limiting membrane peeling in macula-off retinal detachment complicated by grade B proliferative vitreoretinopathy. Am J Ophthalmol. 2018;191:1\u20136. https:\/\/doi.org\/10.1016\/j.ajo.2018.03.037.","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"5455_CR34","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1097\/IAE.0000000000004181","volume":"44","author":"PJ Hughes","year":"2024","unstructured":"Hughes PJ, Bhagat N, Gonzalez-Martinez OG, Zarbin MA. Intravitreal methotrexate injection for the treatment and prevention of proliferative vitreoretinopathy. Retina. 2024;44(10):1748\u201357. https:\/\/doi.org\/10.1097\/IAE.0000000000004181.","journal-title":"Retina"},{"issue":"8","key":"5455_CR35","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.3390\/jcm9082672","volume":"9","author":"Y Jeong","year":"2020","unstructured":"Jeong Y, Ryu JS, Park UC, Oh JY. Corneal Epithelial Toxicity after Intravitreal Methotrexate Injection for Vitreoretinal Lymphoma: Clinical and In Vitro Studies. J Clin Med. 2020;9(8):2672. https:\/\/doi.org\/10.3390\/jcm9082672.","journal-title":"J Clin Med"},{"issue":"4","key":"5455_CR36","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/ICO.0000000000002774","volume":"41","author":"JH Shen-Sampas","year":"2022","unstructured":"Shen-Sampas JH, Ahmad TR, Stewart JM. Corneal Toxicity of Intravitreal Methotrexate Used for the Treatment of Proliferative Vitreoretinopathy in Silicone Oil-Filled Eyes: A Case Series. Cornea. 2022;41(4):499\u2013501. https:\/\/doi.org\/10.1097\/ICO.0000000000002774.","journal-title":"Cornea"},{"issue":"3","key":"5455_CR37","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s40123-026-01332-1","volume":"15","author":"V Verplaetse","year":"2026","unstructured":"Verplaetse V, van Dijk EHC, Faridpooya K. Post-vitrectomy Macular Edema: Shedding Light on Incidence and Risk Factors. Ophthalmol Ther. 2026;15(3):1021\u201331. https:\/\/doi.org\/10.1007\/s40123-026-01332-1.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"5455_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40942-020-00254-9","volume":"7","author":"C Pole","year":"2021","unstructured":"Pole C, Chehaibou I, Govetto A, Garrity S, Schwartz SD, Hubschman JP. Macular edema after rhegmatogenous retinal detachment repair: risk factors, OCT analysis, and treatment responses. Int J Retina Vitr. 2021;7(1):9. https:\/\/doi.org\/10.1186\/s40942-020-00254-9.","journal-title":"Int J Retina Vitr"},{"issue":"1","key":"5455_CR39","doi-asserted-by":"publisher","first-page":"e03230","DOI":"10.1002\/adhm.202503230","volume":"15","author":"M Hammer","year":"2026","unstructured":"Hammer M, Skrzypczyk L, Wohlfart S, et al. Methotrexate-Loaded Liposomal Formulation Enables 6-Week Sustained Intraocular Therapeutic Drug Release in a Porcine Model. Adv Healthc Mater. 2026;15(1):e03230. https:\/\/doi.org\/10.1002\/adhm.202503230.","journal-title":"Adv Healthc Mater"},{"issue":"3","key":"5455_CR40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4103\/0301-4738.81026","volume":"59","author":"EB Ozkan","year":"2011","unstructured":"Ozkan EB, Ozcan AA, Alparslan N. Intravitreal injection of methotrexate in an experimental rabbit model: determination of pharmacokinetics. Indian J Ophthalmol. 2011;59(3):197\u2013200. https:\/\/doi.org\/10.4103\/0301-4738.81026.","journal-title":"Indian J Ophthalmol"},{"issue":"7","key":"5455_CR41","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3390\/pharmaceutics14071364","volume":"14","author":"M Hammer","year":"2022","unstructured":"Hammer M, Schickhardt SK, Merz PR, et al. Intravitreal Application: Physicochemical Properties of Drugs Dissolved in Silicone Oils of Different Density in Comparison to the Porcine Vitreous Body. Pharmaceutics. 2022;14(7):1364. https:\/\/doi.org\/10.3390\/pharmaceutics14071364.","journal-title":"Pharmaceutics"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05455-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05455-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05455-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:02:16Z","timestamp":1792440136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05455-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5455"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-05455-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-10864305\/v1","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"29 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of the University Medicine Rostock und the registration number A 2025-0014 and was conducted in adherence to the tenets of the Declaration of Helsinki. The patients were informed about the off-label use of MTX, and written informed consent was obtained from each patient.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The optical coherence tomography images and clinical data presented are fully anonymized and do not contain any patient-identifying information. Furthermore, institutional informed consent allowing the use of anonymized clinical data and imaging for research and educational purposes was obtained from all patients upon admission.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"661"}}